Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251124 | 0.88 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL18745830 | 0.86 | AR (0.40) | ARCHEK1ACACBDGAT1 | |
| SCHEMBL28897627 | 0.85 | AR (0.44) | ARCHEK1ACACBDGAT1ESR1 | |
| SCHEMBL22752561 | 0.80 | CNR2 (0.38) | ARCHEK1DGAT1CNR2CNR1 | |
| SCHEMBL19251280 | 0.78 | CNR2 (0.38) | ARCHEK1DGAT1CNR2CNR1 | |
| SCHEMBL2739660 | 0.78 | KIF11 (0.44) | ARCHEK1DGAT1KIF11 | |
| SCHEMBL15121088 | 0.75 | CNR2 (0.36) | ARCNR2CNR1ESR1ESR2 | |
| SCHEMBL1584633 | 0.75 | DGAT1 (0.42) | ARCHEK1DGAT1KIF11 | |
| SCHEMBL21553529 | 0.74 | PPARD (0.36) | ARCHEK1 | |
| SCHEMBL21719135 | 0.74 | CNR2 (0.38) | DGAT1CNR2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-20190300506-A1 | SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-10-03 | — | — | US | disclosed |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300506-A1 | SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | STS, SLC5A2, SULT2A1 | AR 1980/4885CHEK1 4680/4885ACACB 1868/4885 |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | AR 4609/4885CHEK1 2415/4885ACACB 585/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | AR 4609/4885CHEK1 2415/4885ACACB 585/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | AR 4609/4885CHEK1 2415/4885ACACB 585/4885 |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | AR 2773/4885CHEK1 530/4885ACACB 4072/4885 |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | STS, SULT2A1, CYP2A13 | AR 1924/4885CHEK1 4102/4885ACACB 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.